2-oxo-1,2-dihydro-[1,8]naphthyridine-3-carboxylic acid amide | 60467-74-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-oxo-1,2-dihydro-[1,8]naphthyridine-3-carboxylic acid amide
• 英文别名: 2-Oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide；2-oxo-1H-1,8-naphthyridine-3-carboxamide
• CAS: 60467-74-5
• 化学式: C₉H₇N₃O₂
• 分子量: 189.173
• InChiKey: ZGPPMEADTREHRZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  85.1
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-氨基-3-吡啶甲醛 、 哌啶 以95%的产率得到
  参考文献：
  名称：

  GORECKI D. K. J.; HAWES E. M., J. MED. CHEM. , 1977, 20, NO 1, 124-128

  摘要：

  DOI：

文献信息

• [EN] COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE<br/>[FR] COMPOSÉS POUR INHIBER DES SOUCHES RÉSISTANTES AUX MÉDICAMENTS D'INTÉGRASE DE VIH-1
  申请人：US HEALTH

  公开号：WO2014186398A1

  公开（公告）日：2014-11-20

  A method of inhibiting drug -resistant HIV-1 integrase in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is N, C(OH), or CH; Y is H or OH; each of Z1-Z5 is independently H or halogen; R4 is H, OH, NH2, NHR8, NR8R9 or R8; R5, R6, and R7 is each independently H, halogen, OR8, R8, NHR8, NR8R9, CO2R8, CONR8R9, SO2NR8R9, or R5 and R6 together with the carbon atoms to which R5 and R6 are attached form an optionally-substituted carbocycle or optionally-substituted heterocycle; and R8 and R9 is each independently H, optionally-substituted alkyl, optionally-substituted alkenyl, optionally- substituted alkynyl, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted cycloalkylene, optionally-substituted heterocycle, optionally-substituted amide, optionally-substituted ester, or R8 and R9 together with the nitrogen to which R8 and R9 are attached form an optionally-substituted heterocycle.

  在需要的患者中给予一种化合物（公式I）的治疗有效量，或其药用盐或酯，以抑制患者体内的耐药HIV-1整合酶。该化合物的结构为：其中X为N、C（OH）或CH；Y为H或OH；Z1-Z5中的每一个独立地为H或卤素；R4为H、OH、NH2、NHR8、NR8R9或R8；R5、R6和R7每一个独立地为H、卤素、OR8、R8、NHR8、NR8R9、CO2R8、CONR8R9、SO2NR8R9，或者R5和R6与其连接的碳原子形成一个可选择取代的碳环或可选择取代的杂环；R8和R9每一个独立地为H、可选择取代的烷基、可选择取代的烯基、可选择取代的炔基、可选择取代的芳基、可选择取代的环烷基、可选择取代的环烷基烯、可选择取代的杂环、可选择取代的酰胺、可选择取代的酯，或者R8和R9与其连接的氮原子形成一个可选择取代的杂环。
• METHODS FOR INCREASING WHITE BLOOD CELLS
  申请人：Fibrogen, Inc.

  公开号：EP2231156A1

  公开（公告）日：2010-09-29
• METHODS FOR INCREASING ENDOTHELIAL PROGENTIOR CELLS
  申请人：Fibrogen, Inc.

  公开号：EP2231157A1

  公开（公告）日：2010-09-29
• METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION
  申请人：Fibrogen, Inc.

  公开号：EP2227232A1

  公开（公告）日：2010-09-15
• COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE
  申请人：The U.S.A. as represented by the Secretary, Department of Health and Human Services

  公开号：EP2996691A1

  公开（公告）日：2016-03-23